Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 2; referees: 2 approved]
Dupuytren’s disease (DD) is a common fibroproliferative condition of the palmar and digital fascia of the hand; however, there is currently no approved treatment for early stage DD. The objective of this paper is to describe the methods applied to assess the cost-effectiveness of adalimumab injectio...
Main Authors: | May Ee Png, Melina Dritsaki, Alastair Gray, Rafael Pinedo-Villanueva, Oliver Rivero-Arias, Jagdeep Nanchahal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wellcome
2019-02-01
|
Series: | Wellcome Open Research |
Online Access: | https://wellcomeopenresearch.org/articles/3-156/v2 |
Similar Items
-
Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 1; referees: 2 approved]
by: May Ee Png, et al.
Published: (2018-12-01) -
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. [version 2; referees: 2 approved]
by: Jagdeep Nanchahal, et al.
Published: (2017-11-01) -
Recent advances in the understanding of Dupuytren’s disease [version 1; referees: 3 approved]
by: Thomas Layton, et al.
Published: (2019-02-01) -
What do we know about managing Dupuytren’s disease cost-effectively?
by: Melina Dritsaki, et al.
Published: (2018-01-01) -
Dupuytren's disease
by: Rames Mattar Junior
Published: (2008-03-01)